Literature DB >> 31638422

Extensively drug-resistant Acinetobacter baumannii isolated from intensive care units in northern Italy: a genomic approach to characterize new sequence types.

Giovanni Lorenzin1,2, Erika Scaltriti3, Franco Gargiulo1, Francesca Caccuri1, Giorgio Piccinelli1, Francesca Gurrieri1, Arnaldo Caruso1, Maria Antonia De Francesco1.   

Abstract

Aim: This study aims to characterize clinical strains of Acinetobacter baumannii with an extensively drug-resistant phenotype.
Methods: VITEK® 2, Etest® method and broth microdilution method for colistin were used. PCR analysis and multilocus sequence typing Pasteur scheme were performed to identify bla-OXA genes and genetic relatedness, respectively. Whole-genome sequencing analysis was used to characterize three isolates.
Results: All the isolates were susceptible only to polymyxins. blaOXA-23-like gene was the only acquired carbapenemase gene in 88.2% of the isolates. Multilocus sequence typing identified various sequence types: ST2, ST19, ST195, ST577 and ST632. Two new sequence types, namely, ST1279 and ST1280, were detected by whole-genome sequencing.
Conclusion: This study showed that carbapenem-resistant A. baumannii isolates causing infections in intensive care units almost exclusively produce OXA-23, underlining their frequent spread in Italy.

Entities:  

Keywords:  OXA-23; PCR; WGS; carbapenem resistance; clonal lineages; virulence

Mesh:

Substances:

Year:  2019        PMID: 31638422     DOI: 10.2217/fmb-2019-0083

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  1 in total

1.  Investigation of Acinetobacter baumannii Activity in Vascular Surgery Units through Epidemiological Management Based on the Analysis of Antimicrobial Resistance, Biofilm Formation and Genotyping.

Authors:  Anna Szczypta; Katarzyna Talaga-Ćwiertnia; Małgorzata Kielar; Paweł Krzyściak; Anna Gajewska; Mirosław Szura; Małgorzata Bulanda; Agnieszka Chmielarczyk
Journal:  Int J Environ Res Public Health       Date:  2021-02-07       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.